Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review.

BACKGROUND

There is a belief that in patients with acromegaly, first-generation somatostatin analogs (SSAs) might improve cardiovascular (CV) structure and function. However, most published clinical trials involved only a few patients and their results are rather variable. We aimed to conduct a systematic review on available studies on the impact of these drugs on CV parameters.

MATERIALS AND METHODS

A literature search was conducted in MEDLINE (OVID), EMBase, Cochrane, and ISI Web of Science for citations published until April 30 2018 to identify studies on our objective that considered changes in CV parameters. For this search, we established a Boolean search strategy using keywords related to "acromegaly," "Somatostatin analog," and "cardiovascular diseases and parameters." All study types except for case reports or conference abstracts were included. Twenty-four studies ( = 558) fulfilled the inclusion criteria and were selected for final analysis.

RESULTS

In 12 studies ( = 350), decrease in heart rate (HR) and in 4 studies ( = 128), decrease in blood pressure (BP) was significant. In 15 studies ( = 320), left ventricular mass index (LVMi) changes were significant. In 9 studies ( = 202), the early diastole to peak velocity flow in late diastole (E/A ratio) was evaluated, and in 5 of them ( = 141), the improvement was significant. Eighteen studies ( = 366) examined changes in left ventricular ejection fraction (LVEF), 5 of which ( = 171) reported that these changes were significant. Decrease of left ventricular end-diastolic diameter was reported in only 2 studies ( = 27).

CONCLUSION

We found that first-generation SSAs have a beneficial effect on cardiac parameters such as HR and LVMi. For other parameters such as LVEF, BP, LV diameter, and E/A ratio, we were not able to draw a firm conclusion.